pbms ftc report - Search News

Big 3 PBMs reaped $7.3B from generic specialty drug markups

Hosted on MSN · 3d

PBMs made more than $7B marking up specialty generics: FTC

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.

The Hill on MSN · 3d

PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through

pharmaphorum · 3d

FTC doubles down on PBM criticism in new report

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, cardiovascular diseases, and HIV, specifically, the big three players in the sector – CVS' Caremark,

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

ConsumerAffairs3d

Another FTC report is highly critical of pharmacy benefit managers

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

1don MSN

New legislation aims to prevent PBMs from controlling drug pricing and pharmacy ownership

The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...

21h

More Litigation Coming? Insulin MDL Gets Boost from FTC Report

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results